AbbVie Stock: Is it REALLY one of the Best Value Stocks in 2020?

AbbVie Stock Analysis: Is it Overrated?

Many Wall Street investors have ranked Abbvie in the top 10 value stocks among the best dividend stocks 2020. The Abbvie stock erased the COVID-19 related losses on June 9th, 2020. Now the question is, what’s next for this stock in terms of price.

In this video, I analyze the Abbvie stock (ABBV) from the 5 points of my signature Invest Diva Diamond analysis which (IDDA) to find out if it really is among the best stocks to buy now, what type of investors should look into adding ABBV to their investment portfolio, what price you can consider buying, how long you can consider holding on to it before taking profit, and whether or not AbbVie is among my personal “top stocks to buy now” list.

New to investing? Start off the right way >>

Abbvie Stock Analysis – Fundamentals

Abbvie, which is a drug company most famous for its rheumatoid arthritis drug, Humira, that you probably have heard of during ad breaks on your TV, and it’s the one that goes on and on about the side effects to the point that you lose track which disease the drug actually cures and lose the will to live because of the possible side effects a simple drug can cause you.

How Wall Street Ranks AbbVie Stock

The Abbvie stock pays really high dividend payments at around 4.99% yield. And Seeking Alpha’s quant and Wall Street Analysis have ranked it in the top 10 stocks to buy, grading it A+ in terms of profitability, A in terms of growth and value.

But is Abbvie really as good as Wall Street wants us to believe?

That’s up for debate because unlike its competition in this category, more than 50% of Abbvie’s sales come from only 1 product, and that is Humira. Now Humira is certainly the leady drug in its category and is protected by a number of patents which gives it a competitive advantage… But the risk here is if there’s a drug pricing cut by a larger player, or if there’s any new competitive threats to Humira, both from biosimilars and new branded drug competition.

Also, AbbVie has taken on significant debt to purchase Allergan, but that actually may be a good thing because it could lead to a robust cash flows that will help manage the heavy debt load.

Overall, I would put AbbVie at a medium risk level but this could be leveled off if you’re investing in it mainly for the dividend payment cashflow.

If you’d like to see the full list of my top long-term holds, dividend-paying stocks, tech stocks, and growth stocks, along with 10 financial assets that I like more than AbbVie, click here to join Invest Diva’s Premium Investing Group aka PIG.

You might also like: Tesla Stock Price Analysis 2020 | Is TSLA Still A Good Buy Or Did You Miss Out?

AbbVie Stock Price – Technical Analysis

The AbbView Stock price (ABBV) has once again hit the 61% Fibonacci resistance level of $97. A pullback here could indicate a formation of a double top bearish reversal chart pattern.

The price remains above the daily Ichimoku cloud. The support levels could be an optimal buying price for those who are looking to add the AbbVie stock to their portfolio. The key support levels are 87, 79 and 68.

Please watch this video for the full technical analysis.

Check out my book Ichimoku Secrets.

Find out about the 10 stocks I like more than NIO by becoming a Premium Investing Group (PIG) member.

How To Take Control Of Your Financial Future >>

VIDEOS YOU’LL LOVE

Kiana Danial

#1 Best Selling Author. Helping you accelerate your retirement with Triple Compounding™ Former engineer on a mission to help 1 million households take control of their finances. Founder & CEO of Invest Diva.

Bitcoin Drops Entering 2026: Is It Still Worth Investing? The Answer Most Investors Miss

January 2, 2026 No Comments

Bitcoin has entered 2026 under pressure, with prices pulling back after a volatile period that left many investors questioning whether the opportunity has passed. Headlines are once again split between fear and optimism, with some calling the recent drop a warning sign and others viewing it as a healthy reset.

Unlike speculative assets that rely on constant growth stories, Bitcoin’s relevance continues to rest on its role as a scarce, decentralised digital asset that operates outside traditional financial systems. The key question for investors now is not whether Bitcoin will remain volatile – but whether this moment represents risk, opportunity, or something most investors misunderstand.

3 Bullish And 3 Risky Forces Shaping American Express Stock (AXP) Into 2026

December 26, 2025 No Comments

American Express is often viewed as a mature, well understood credit card company, but its role in the financial system is broader than many investors realize.

It sits at the center of consumer spending, business payments, travel, credit risk, and data driven decision making. As these areas evolve, the dynamics shaping American Express stock are becoming more complex and, in some cases, less obvious.

Premium consumer behavior, business spending patterns, regulatory scrutiny, and technological change are all influencing how payment companies operate and compete.

Micron Stock Surges After Blowout Earnings: Is MU Still A Buy In 2026?

December 19, 2025 No Comments

Micron Technology (NASDAQ: MU) has quietly become one of the most important companies supporting the AI boom – even if it doesn’t receive the same attention as Nvidia or other high-profile AI names.

While much of the focus is on GPUs and AI software, Micron operates behind the scenes, supplying the memory that allows AI systems, data centres, and cloud platforms to function at scale.

Following a strong earnings update, Micron’s stock surged and quickly returned to the centre of market attention. The rally reflects growing confidence that the company’s strategic shift away from lower margin consumer products toward higher-value enterprise and data-centre memory is gaining traction.

Why Big Tech Is Quietly Buying Western Digital (WDC) Stock

December 12, 2025 No Comments

Western Digital Corporation (WDC) has been on a tear, its stock price soaring over 270% year-to-date as of early December 2025.

This massive growth isn’t just hype; it’s fueled by a perfect storm of events, including the strategic spin-off of its flash business, SanDisk, and an insatiable global demand for data storage driven by the AI revolution.

As a now “pure-play” Hard Disk Drive (HDD) manufacturer, WDC is uniquely positioned as the landlord for the internet’s exploding data. But with such a meteoric rise, is there still room for growth, or is the stock overheated?

Marvell (MRVL) Stock: The Hidden AI Powerhouse Wall Street Keeps Underestimating

December 5, 2025 No Comments

Marvell Technology (NASDAQ: MRVL) is quickly becoming one of the most important companies in the AI infrastructure space – even though many investors still aren’t sure what the business actually does.

While most headlines focus on Nvidia and its GPUs, Marvell builds the networking, optical, and custom silicon chips that help AI models move data faster and run more efficiently. In its latest earnings report, Marvell posted strong double-digit growth in its data center business and shared bold guidance for the next few years, sending MRVL stock higher.

2 Months Ago Oracle Stock (ORCL) Was Flying And Now… The Mood Has Flipped. Is A Comeback Still On The Table?

November 28, 2025 No Comments

Oracle is one of the biggest names in enterprise software and cloud services. They power databases used by governments, banks, hospitals, airlines, and global corporations. For years they were known for steady tech growth, not big surprises.

Then something wild happened.

Only two months ago Oracle stock was flying. Analysts cheered. AI deals stacked up. The company felt like it had finally stepped into a new era.

Now the mood has flipped.